Advanced Targeting Systems

Chronic pain is often difficult to pinpoint--witness the strange phenomenon of phantom limb pain, where patients continue to feel pain years after an amputation. Advanced Targeting Systems believes it can target a toxin known as saporin to the neurons that express substance P receptors, to permanently knock out chronic pain while leaving useful pain sensation intact.

"Pain is good," asserts Douglas Lappi, PhD, president and founder of Advanced Targeting Systems . "People who lack the ability to sense pain have very shortened life spans." The trick, says Lappi, is to short-circuit the signals that cause chronic, intractable pain and leave intact the body's ability to detect incoming pain stimuli like heat, chemicals, or injury. In the US, 70 million people suffer from chronic pain. Many disorders cause people to become hypersensitive to stimuli that otherwise would not cause pain. Many people also suffer from pain that persists in the absence of an ongoing injury, such as sufferers of phantom limb pain, reflex sympathetic dystrophy, and diabetic neuropathy. The company believes it has found a solution to these types of pain syndromes in the permanent elimination of neurons in the spinal cord which express receptors for substance P.

Substance P is a neurotransmitter that is implicated in several disorders, including cancer, asthma, emesis, depression, and pain. Capsaicin, a topical anesthetic isolated from chili peppers is the only approved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.